Publication Date
| In 2024 | 0 |
| Since 2023 | 0 |
| Since 2020 (last 5 years) | 0 |
| Since 2015 (last 10 years) | 0 |
| Since 2005 (last 20 years) | 6 |
Descriptor
| Attention Deficit Disorders | 6 |
| Drug Therapy | 6 |
| Hyperactivity | 5 |
| Outcomes of Treatment | 5 |
| Children | 3 |
| Pharmacology | 3 |
| Severity (of Disability) | 3 |
| Stimulants | 3 |
| Symptoms (Individual… | 3 |
| Adolescents | 2 |
| Body Height | 2 |
| More ▼ | |
Author
Publication Type
| Journal Articles | 6 |
| Reports - Research | 4 |
| Reports - Descriptive | 1 |
| Reports - Evaluative | 1 |
Education Level
Audience
Location
Laws, Policies, & Programs
Assessments and Surveys
What Works Clearinghouse Rating
Peer reviewed
Direct linkFaraone, Stephen V.; Spencer, Thomas J.; Kollins, Scott H.; Glatt, Stephen J.; Goodman, David – Journal of Attention Disorders, 2012
Objective: To explore dose-response effects of lisdexamfetamine dimesylate (LDX) treatment for ADHD. Method: This was a 4-week, randomized, double-blinded, placebo-controlled, parallel-group, forced-dose titration study in adult participants, aged 18 to 55 years, meeting "Diagnostic and Statistical Manual of Mental Disorders" (4th ed., text rev.)…
Descriptors: Attention Deficit Disorders, Rating Scales, Severity (of Disability), Drug Therapy
Faraone, Stephen V.; Biederman, Joseph; Morley, Christopher P.; Spencer, Thomas J. – Journal of the American Academy of Child & Adolescent Psychiatry, 2008
The article reviews existing literature on the effects of stimulant medications on the growth of children with attention-deficit/hyperactivity disorder. It concludes that treatment with stimulants in childhood results in moderate growth deficit in height and weight.
Descriptors: Stimulants, Hyperactivity, Attention Deficit Disorders, Body Weight
Spencer, Thomas J.; Sallee, F. Randy; Gilbert, Donald L.; Dunn, David W.; McCracken, James T.; Coffey, Barbara J.; Budman, Cathy L.; Ricardi, Randall K.; Leonard, Henrietta L.; Allen, Albert J.; Milton, Denai R.; Feldman, Peter D.; Kelsey, Douglas K.; Geller, Daniel A.; Linder, Steven L.; Lewis, Donald W.; Winner, Paul K.; Kurlan, Roger M.; Mintz, Mark – Journal of Attention Disorders, 2008
Objective: This study examines changes in severity of tics and ADHD during atomoxetine treatment in ADHD patients with Tourette syndrome (TS). Method: Subjects (7-17 years old) with ADHD ("Diagnostic and Statistical Manual of Mental Disorders, DSM-IV") and TS were randomly assigned to double-blind treatment with placebo (n = 56) or atomoxetine…
Descriptors: Metabolism, Attention Deficit Disorders, Patients, Severity (of Disability)
Biederman, Joseph; Spencer, Thomas J.; Wilens, Timothy E.; Prince, Jefferson B.; Faraone, Stephen V. – Journal of the American Academy of Child and Adolescent Psychiatry, 2006
This article is a response to Dr. Steven E. Nissen's comments (Nissen, 2006) about attention deficit/hyperactivity disorder (ADHD) and its treatment with stimulant medications. In this article, the authors refute his arguments and provide accurate information. Here, they answer the questions, such as: (1) Do stimulants increase the risk for sudden…
Descriptors: Stimulants, Hyperactivity, Attention Deficit Disorders, Risk
Spencer, Thomas J.; Faraone, Stephen V.; Biederman, Joseph; Lerner, Marc; Cooper, Kimberly M.; Zimmerman, Brenda – Journal of the American Academy of Child and Adolescent Psychiatry, 2006
Objective: To investigate whether prolonged therapy with a long-acting stimulant affects growth in children with attention-deficit/hyperactivity disorder (ADHD). Method: One hundred seventy-eight children ages 6 to 13 years received OROS methylphenidate (OROS MPH, CONCERTA) for at least 21 months. Height and weight were measured monthly during the…
Descriptors: Body Height, Body Weight, Drug Therapy, Stimulants
Doyle, Robert L.; Frazier, Jean; Spencer, Thomas J.; Geller, Daniel; Biederman, Joseph; Wilens, Timothy – Journal of Attention Disorders, 2006
Background: Recent studies reported ADHD-like symptoms and cognitive deficits in pervasive developmental disorder (PDD). Because work in dementia documents improvement in executive function deficits with the acetylcholinesterase inhibitor donepezil, the authors reason that similar benefits could be obtained in PDD. Method: The authors describe…
Descriptors: Pervasive Developmental Disorders, Attention Deficit Disorders, Hyperactivity, Symptoms (Individual Disorders)
